Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

On January 2, 2019 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, reported that Matthew R. Patterson, Chairman and Chief Executive Officer, will provide a corporate overview and 2019 outlook at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA (Press release, Audentes Therapeutics, JAN 2, 2019, View Source [SID1234532343]). The presentation is scheduled for Tuesday, January 8, 2019, at 3:30 pm PST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentations, please visit the Events & Presentations page within the Investors & News section of the Audentes website. Replays of live webcasts will be available on the Audentes website for approximately 30 days following the conferences.